Clinical Trial Update: Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of trastuzumab deruxtecan in HER2-overexpressing advanced or metastatic colorectal cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Advanced Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-01-02